e-Pharmatimes

Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025) The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries . 🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound. 1. The Core Dispute At the heart of this litigation is Indian Patent No. 262697 . Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active p...

Delhi High Court Ruling: Novo Nordisk vs Sun Pharma on Semaglutide Litigation Update: Novo Nordisk vs Sun Pharma on Semaglutide The Delhi High Court has passed a crucial order in the ongoing patent battle between Danish pharmaceutical giant Novo Nordisk and Indian major Sun Pharma regarding the manufacture and sale of Semaglutide . Key Takeaways from the Order Export Allowed: Sun Pharma has been permitted to manufacture and export Semaglutide to countries where Novo Nordisk does not hold a valid patent. Domestic Sales Barred: The court has restrained Sun Pharma from selling the drug in the Indian market until the expiry of Novo Nordisk's specific patent in March 2026. Undertaking Recorded: Justice Manmeet Pritam Singh Arora recorded Sun Pharma's undertaking that it would not commercialize the product in India during the patent term. Background of the Dispute ...

Weight Loss Drugs and the Indian Pharmaceutical Economy: A New Era of Health and Business 💊 The New Revolution in Weight Loss: Beyond Diets and Gyms Weight management is no longer limited to gym routines and calorie counting. India’s healthcare landscape is witnessing a scientific revolution driven by advanced weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) . These modern therapies are reshaping the country’s pharmaceutical economy, creating new business opportunities for both global and Indian companies. 🇮🇳 India’s Weight Loss Drug Boom in 2025 According to Reuters , India’s weight loss drug market crossed ₹600 crore in mid-2025 — a growth rate few other pharma categories can match. Global giants like Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy) are driving the wave, while Indian companies such as Dr. Reddy’s, Lupin, Zydus, and Sun Pharma are fast-tracking their own anti-obesity formulations. For perspective, Mounjaro was launched ...